| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8441002 | European Journal of Cancer | 2016 | 8 Pages |
Abstract
Intraperitoneal bevacizumab was well tolerated. Overall, treatment did not result in a significantly better symptom control of malignant ascites. However, patients defined by specific immune characteristics may benefit.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
K. Jordan, T. Luetkens, C. Gog, B. Killing, D. Arnold, A. Hinke, M. Stahl, W. Freier, J. Rüssel, D. Atanackovic, S. Hegewisch-Becker,